Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, showing that the drug met its primary endpoint in the treatment of single migraine attack of moderate-to-severe intensity in adult patients.
Original Article: Allergan unveils second bout of Phase 3 success in migraine